{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:34:09Z","timestamp":1776299649969,"version":"3.50.1"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12936-017-2062-y","type":"journal-article","created":{"date-parts":[[2017,10,23]],"date-time":"2017-10-23T19:00:21Z","timestamp":1508785221000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates"],"prefix":"10.1186","volume":"16","author":[{"given":"Maarten","family":"van der Velden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Bilos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeroen J. M. W.","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanna R.","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelien G. E.","family":"Hurkmans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert W.","family":"Sauerwein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frans G. M.","family":"Russel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan B.","family":"Koenderink","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,23]]},"reference":[{"key":"2062_CR1","unstructured":"WHO. Malaria fact sheet no. 94. Geneva: World Health Organization; 2015."},{"key":"2062_CR2","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015."},{"key":"2062_CR3","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1097\/01.aids.0000174445.40379.e0","volume":"19","author":"S Khoo","year":"2005","unstructured":"Khoo S, Back D, Winstanley P. The potential for interactions between antimalarial and antiretroviral drugs. AIDS. 2005;19:995\u20131005.","journal-title":"AIDS"},{"key":"2062_CR4","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1097\/QAD.0b013e3283389129","volume":"24","author":"M Luin van","year":"2010","unstructured":"van Luin M, Van der Ende ME, Richter C, Visser M, Faraj D, Van der Ven A, et al. Lower atovaquone\/proguanil concentrations in patients taking efavirenz, lopinavir\/ritonavir or atazanavir\/ritonavir. AIDS. 2010;24:1223\u20136.","journal-title":"AIDS"},{"key":"2062_CR5","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejps.2009.11.012","volume":"39","author":"JO Soyinka","year":"2010","unstructured":"Soyinka JO, Onyeji CO. Alteration of pharmacokinetics of proguanil in healthy volunteers following concurrent administration of efavirenz. Eur J Pharm Sci. 2010;39:213\u20138.","journal-title":"Eur J Pharm Sci"},{"key":"2062_CR6","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/QAI.0b013e3181acb4ff","volume":"51","author":"P German","year":"2009","unstructured":"German P, Parikh S, Lawrence J, Dorsey G, Rosenthal PJ, Havlir D, et al. Lopinavir\/ritonavir affects pharmacokinetic exposure of artemether\/lumefantrine in HIV-uninfected healthy volunteers. J Acquir Immune Defic Syndr. 2009;51:424\u20139.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2062_CR7","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1093\/jac\/dkn330","volume":"62","author":"M Sousa","year":"2008","unstructured":"Sousa M, Pozniak A, Boffito M. Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs. J Antimicrob Chemother. 2008;62:872\u20138.","journal-title":"J Antimicrob Chemother"},{"key":"2062_CR8","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/j.1365-2125.1995.tb04541.x","volume":"40","author":"S Wanwimolruk","year":"1995","unstructured":"Wanwimolruk S, Kang W, Coville PF, Viriyayudhakorn S, Thitiarchakul S. Marked enhancement by rifampicin and lack of effect of isoniazid on the elimination of quinine in man. Br J Clin Pharmacol. 1995;40:87\u201391.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/1743-7075-5-27","volume":"5","author":"Z Bibi","year":"2008","unstructured":"Bibi Z. Role of cytochrome P450 in drug interactions. Nutr Metab (Lond). 2008;5:27.","journal-title":"Nutr Metab (Lond)"},{"key":"2062_CR10","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2217\/pgs.11.44","volume":"12","author":"F Muller","year":"2011","unstructured":"Muller F, Fromm MF. Transporter-mediated drug\u2013drug interactions. Pharmacogenomics. 2011;12:1017\u201337.","journal-title":"Pharmacogenomics"},{"key":"2062_CR11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1186\/1475-2875-13-359","volume":"13","author":"SR Rijpma","year":"2014","unstructured":"Rijpma SR, van den Heuvel JJ, van der Velden M, Sauerwein RW, Russel FG, Koenderink JB. Atovaquone and quinine anti-malarials inhibit ATP binding cassette transporter activity. Malar J. 2014;13:359.","journal-title":"Malar J"},{"key":"2062_CR12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1089\/dna.1997.16.871","volume":"16","author":"V Gorboulev","year":"1997","unstructured":"Gorboulev V, Ulzheimer JC, Akhoundova A, Ulzheimer-Teuber I, Karbach U, Quester S, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997;16:871\u201381.","journal-title":"DNA Cell Biol"},{"key":"2062_CR13","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00210-007-0219-x","volume":"376","author":"AT Nies","year":"2008","unstructured":"Nies AT, Herrmann E, Brom M, Keppler D. Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1). Naunyn Schmiedebergs Arch Pharmacol. 2008;376:449\u201361.","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2062_CR14","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1681\/ASN.V134866","volume":"13","author":"H Motohashi","year":"2002","unstructured":"Motohashi H, Sakurai Y, Saito H, Masuda S, Urakami Y, Goto M, et al. Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J Am Soc Nephrol. 2002;13:866\u201374.","journal-title":"J Am Soc Nephrol"},{"key":"2062_CR15","doi-asserted-by":"crossref","first-page":"17923","DOI":"10.1073\/pnas.0506483102","volume":"102","author":"M Otsuka","year":"2005","unstructured":"Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y. A human transporter protein that mediates the final excretion step for toxic organic cations. Proc Natl Acad Sci USA. 2005;102:17923\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2062_CR16","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1681\/ASN.2006030205","volume":"17","author":"S Masuda","year":"2006","unstructured":"Masuda S, Terada T, Yonezawa A, Tanihara Y, Kishimoto K, Katsura T, et al. Identification and functional characterization of a new human kidney-specific H+\/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J Am Soc Nephrol. 2006;17:2127\u201335.","journal-title":"J Am Soc Nephrol"},{"key":"2062_CR17","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1093\/nar\/11.21.7631","volume":"11","author":"CM Gorman","year":"1983","unstructured":"Gorman CM, Howard BH, Reeves R. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res. 1983;11:7631\u201348.","journal-title":"Nucleic Acids Res"},{"key":"2062_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"International-Transporter-Consortium, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9:215\u201336.","journal-title":"Nat Rev Drug Discov"},{"key":"2062_CR19","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0022-3565(24)29357-5","volume":"298","author":"JE Montfoort van","year":"2001","unstructured":"van Montfoort JE, Muller M, Groothuis GM, Meijer DK, Koepsell H, Meier PJ. Comparison of \u201ctype I\u201d and \u201ctype II\u201d organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001;298:110\u20135.","journal-title":"J Pharmacol Exp Ther"},{"key":"2062_CR20","doi-asserted-by":"crossref","first-page":"5932","DOI":"10.1021\/jm8003152","volume":"51","author":"G Ahlin","year":"2008","unstructured":"Ahlin G, Karlsson J, Pedersen JM, Gustavsson L, Larsson R, Matsson P, et al. Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1. J Med Chem. 2008;51:5932\u201342.","journal-title":"J Med Chem"},{"key":"2062_CR21","doi-asserted-by":"crossref","first-page":"4548","DOI":"10.1021\/jm2001629","volume":"54","author":"Y Kido","year":"2011","unstructured":"Kido Y, Matsson P, Giacomini KM. Profiling of a prescription drug library for potential renal drug\u2013drug interactions mediated by the organic cation transporter 2. J Med Chem. 2011;54:4548\u201358.","journal-title":"J Med Chem"},{"key":"2062_CR22","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S0022-3565(24)36460-2","volume":"280","author":"C Funck-Brentano","year":"1997","unstructured":"Funck-Brentano C, Becquemont L, Lenevu A, Roux A, Jaillon P, Beaune P. Inhibition by omeprazole of proguanil metabolism: mechanism of the interaction in vitro and prediction of in vivo results from the in vitro experiments. J Pharmacol Exp Ther. 1997;280:730\u20138.","journal-title":"J Pharmacol Exp Ther"},{"key":"2062_CR23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/01.qai.0000219774.20174.64","volume":"42","author":"RF Yeh","year":"2006","unstructured":"Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, et al. Lopinavir\/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr. 2006;42:52\u201360.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2062_CR24","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1111\/j.1365-2125.2007.03085.x","volume":"65","author":"B Damle","year":"2008","unstructured":"Damle B, LaBadie R, Crownover P, Glue P. Pharmacokinetic interactions of efavirenz and voriconazole in healthy volunteers. Br J Clin Pharmacol. 2008;65:523\u201330.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR25","first-page":"78","volume":"6","author":"DM Moss","year":"2015","unstructured":"Moss DM, Liptrott NJ, Siccardi M, Owen A. Interactions of antiretroviral drugs with the SLC22A1 (OCT1) drug transporter. Front Pharmacol. 2015;6:78.","journal-title":"Front Pharmacol"},{"key":"2062_CR26","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1365-2125.1999.00071.x","volume":"48","author":"P Villani","year":"1999","unstructured":"Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R. Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol. 1999;48:712\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR27","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1128\/AAC.02329-12","volume":"57","author":"LB Avery","year":"2013","unstructured":"Avery LB, Sacktor N, McArthur JC, Hendrix CW. Protein-free efavirenz concentrations in cerebrospinal fluid and blood plasma are equivalent: applying the law of mass action to predict protein-free drug concentration. Antimicrob Agents Chemother. 2013;57:1409\u201314.","journal-title":"Antimicrob Agents Chemother"},{"key":"2062_CR28","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1086\/511882","volume":"44","author":"P German","year":"2007","unstructured":"German P, Greenhouse B, Coates C, Dorsey G, Rosenthal PJ, Charlebois E, et al. Hepatotoxicity due to a drug interaction between amodiaquine plus artesunate and efavirenz. Clin Infect Dis. 2007;44:889\u201391.","journal-title":"Clin Infect Dis"},{"key":"2062_CR29","doi-asserted-by":"crossref","first-page":"F997","DOI":"10.1152\/ajprenal.00431.2009","volume":"298","author":"HE Meyer zu Schwabedissen","year":"2010","unstructured":"Meyer zu Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1\/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010;298:F997\u20131005.","journal-title":"Am J Physiol Renal Physiol"},{"key":"2062_CR30","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/clpt.2011.36","volume":"89","author":"H Kusuhara","year":"2011","unstructured":"Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89:837\u201344.","journal-title":"Clin Pharmacol Ther"},{"key":"2062_CR31","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1016\/j.bcp.2005.09.011","volume":"70","author":"J Muller","year":"2005","unstructured":"Muller J, Lips KS, Metzner L, Neubert RH, Koepsell H, Brandsch M. Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005;70:1851\u201360.","journal-title":"Biochem Pharmacol"},{"key":"2062_CR32","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.2009.03566.x","volume":"69","author":"JO Soyinka","year":"2010","unstructured":"Soyinka JO, Onyeji CO, Omoruyi SI, Owolabi AR, Sarma PV, Cook JM. Pharmacokinetic interactions between ritonavir and quinine in healthy volunteers following concurrent administration. Br J Clin Pharmacol. 2010;69:262\u201370.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR33","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1124\/dmd.108.020826","volume":"36","author":"N Jung","year":"2008","unstructured":"Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos. 2008;36:1616\u201323.","journal-title":"Drug Metab Dispos"},{"key":"2062_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00007691-200502000-00014","volume":"27","author":"PH Hinderling","year":"2005","unstructured":"Hinderling PH, Hartmann D. The pH dependency of the binding of drugs to plasma proteins in man. Ther Drug Monit. 2005;27:71\u201385.","journal-title":"Ther Drug Monit"},{"key":"2062_CR35","doi-asserted-by":"crossref","first-page":"336","DOI":"10.2165\/00003088-198207040-00004","volume":"7","author":"E Perucca","year":"1982","unstructured":"Perucca E, Crema A. Plasma protein binding of drugs in pregnancy. Clin Pharmacokinet. 1982;7:336\u201352.","journal-title":"Clin Pharmacokinet"},{"key":"2062_CR36","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/j.2042-7158.1992.tb03210.x","volume":"44","author":"S Wanwimolruk","year":"1992","unstructured":"Wanwimolruk S, Denton JR. Plasma protein binding of quinine: binding to human serum albumin, alpha 1-acid glycoprotein and plasma from patients with malaria. J Pharm Pharmacol. 1992;44:806\u201311.","journal-title":"J Pharm Pharmacol"},{"key":"2062_CR37","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1365-2125.1991.tb03904.x","volume":"32","author":"K Silamut","year":"1991","unstructured":"Silamut K, Molunto P, Ho M, Davis TM, White NJ. Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. Br J Clin Pharmacol. 1991;32:311\u20135.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR38","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/0002-9343(82)90337-0","volume":"73","author":"NJ White","year":"1982","unstructured":"White NJ, Looareesuwan S, Warrell DA, Warrell MJ, Bunnag D, Harinasuta T. Quinine pharmacokinetics and toxicity in cerebral and uncomplicated Falciparum malaria. Am J Med. 1982;73:564\u201372.","journal-title":"Am J Med"},{"key":"2062_CR39","unstructured":"GlaxoSmithKline Inc. Malarone. GSK Product Monograph. Research Triangle Park, NC, GSK. 2004."},{"key":"2062_CR40","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2125.1996.tb00179.x","volume":"41","author":"AA Somogyi","year":"1996","unstructured":"Somogyi AA, Reinhard HA, Bochner F. Pharmacokinetic evaluation of proguanil: a probe phenotyping drug for the mephenytoin hydroxylase polymorphism. Br J Clin Pharmacol. 1996;41:175\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"2062_CR41","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bcp.2007.04.010","volume":"74","author":"Y Tanihara","year":"2007","unstructured":"Tanihara Y, Masuda S, Sato T, Katsura T, Ogawa O, Inui K. Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions\/H(+)-organic cation antiporters. Biochem Pharmacol. 2007;74:359\u201371.","journal-title":"Biochem Pharmacol"},{"key":"2062_CR42","doi-asserted-by":"crossref","first-page":"379","DOI":"10.2133\/dmpk.20.379","volume":"20","author":"N Kimura","year":"2005","unstructured":"Kimura N, Masuda S, Tanihara Y, Ueo H, Okuda M, Katsura T, Inui K. Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005;20:379\u201386.","journal-title":"Drug Metab Pharmacokinet"},{"key":"2062_CR43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11095-004-1193-3","volume":"22","author":"N Kimura","year":"2005","unstructured":"Kimura N, Okuda M, Inui K. Metformin transport by renal basolateral organic cation transporter hOCT2. Pharm Res. 2005;22:255\u20139.","journal-title":"Pharm Res"},{"key":"2062_CR44","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1172\/JCI30558","volume":"117","author":"Y Shu","year":"2007","unstructured":"Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Investig. 2007;117:1422\u201331.","journal-title":"J Clin Investig"},{"key":"2062_CR45","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1128\/AAC.00679-09","volume":"54","author":"J Mwesigwa","year":"2010","unstructured":"Mwesigwa J, Parikh S, McGee B, German P, Drysdale T, Kalyango JN, et al. Pharmacokinetics of artemether\u2013lumefantrine and artesunate\u2013amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother. 2010;54:52\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"2062_CR46","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2165\/00003088-200140050-00003","volume":"40","author":"PT Giao","year":"2001","unstructured":"Giao PT, de Vries PJ. Pharmacokinetic interactions of antimalarial agents. Clin Pharmacokinet. 2001;40:343\u201373.","journal-title":"Clin Pharmacokinet"},{"key":"2062_CR47","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0035-9203(98)90749-0","volume":"92","author":"A Sabchareon","year":"1998","unstructured":"Sabchareon A, Attanath P, Phanuaksook P, Chanthavanich P, Poonpanich Y, Mookmanee D, et al. Efficacy and pharmacokinetics of atovaquone and proguanil in children with multidrug-resistant Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg. 1998;92:201\u20136.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2062_CR48","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.clpt.2006.08.016","volume":"80","author":"KI Barnes","year":"2006","unstructured":"Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine-pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80:582\u201396.","journal-title":"Clin Pharmacol Ther"},{"key":"2062_CR49","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1023\/A:1015947301890","volume":"7","author":"AC Rudy","year":"1990","unstructured":"Rudy AC, Poynor WJ. Binding of pyrimethamine to human plasma proteins and erythrocytes. Pharm Res. 1990;7:1055\u201360.","journal-title":"Pharm Res"},{"key":"2062_CR50","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1128\/AAC.47.11.3458-3463.2003","volume":"47","author":"S Pukrittayakamee","year":"2003","unstructured":"Pukrittayakamee S, Wanwimolruk S, Stepniewska K, Jantra A, Huyakorn S, Looareesuwan S, White NJ. Quinine pharmacokinetic-pharmacodynamic relationships in uncomplicated Falciparum malaria. Antimicrob Agents Chemother. 2003;47:3458\u201363.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-017-2062-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T17:45:08Z","timestamp":1750959908000},"score":1,"resource":{"primary":{"URL":"http:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-017-2062-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,23]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["2062"],"URL":"https:\/\/doi.org\/10.1186\/s12936-017-2062-y","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,10,23]]},"article-number":"422"}}